Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related ...
Morningstar· 1 day agoKinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and potential advantages of KIN001 ...
LumiThera Presents US LIGHTSITE III Trial Data Showing Improvement in Vision in Intermediate Dry...
WFMZ Eastern Pennsylvania and Western New Jersey· 3 days agoSEATTLE, June 22, 2022 /PRNewswire/ -- LumiThera Inc., a commercial stage medical device company...
NGM Biopharmaceuticals: Eye Disorder Data Due 2nd Half Of 2022 (NASDAQ:NGM)
Seeking Alpha· 4 days agoThis will be the release of results from the phase 2 CATALINA study using NGM621 for the treatment...
Adverum Biotechnologies Obtains EMA’s Priority Medicines Status For Chronic Eye Disorder Candidate -...
Benzinga· 15 hours agoThe European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to Adverum Biotechnologies’ ADVM lead drug ADVM-022 for the treatment of wet age-related ...
Vision changes after 40? Here's what you need to know
The Port Lavaca Wave· 8 hours agoThe American Academy of Ophthalmology (AAO) suggests everyone see an ophthalmologist for a baseline eye disease screening at age 40, even if there are no apparent problems with their vision.
Apellis (APLS) Expands Deal for Targeted Complement Therapies
Zacks via Yahoo Finance· 2 days agoApellis (APLS) expands its current research and development deal with privately held company,...
Cost of ranibizumab port delivery system for treating nAMD examined
Medical Xpress· 2 days agoFor patients with neovascular age-related macular degeneration (nAMD), ranibizumab with a port...
Supplements warning: The vitamin linked to a ‘rapid' reduction in vision ‘over minutes'
MSN News· 2 hours agoUNLIKE drugs, supplements are not intended to treat, prevent or cure diseases, but instead are...
Kubota Vision Announced End of Phase 3 Clinical Trial of Emixustat in Patients with Stargardt...
Morningstar· 14 hours ago(Tokyo 4596), announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride (“emixustat”) in patients with macular atrophy secondary to ...
EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors
Morningstar· 2 days agoDr. Adamis is a highly accomplished ophthalmology executive with more than 30 years of research and development experience in the biopharmaceutical industry. “Dr. Adamis is a pioneer in the ...
Yahoo Web Search
Trending Now
